Clinical Trials Logo

Choledochal Cyst clinical trials

View clinical trials related to Choledochal Cyst.

Filter by:

NCT ID: NCT06162520 Completed - Clinical trials for Congenital Biliary Dilatation

Congenital Biliary Dilatation Diagnosis Based on 3D Morphological Characteristics

Start date: December 17, 2021
Phase:
Study type: Observational

Congenital biliary dilatation necessitates timely intervention owing to potential complications. This study endeavors to enhance diagnostic precision using quantitative three-dimensional morphological characteristics. Objectives involve developing models to differentiate congenital from secondary biliary dilatation and identify intrahepatic involvement. Employing machine learning, robust diagnostic models aim to elevate clinical detection rates and improve accuracy.

NCT ID: NCT06111872 Recruiting - Pancreatic Cancer Clinical Trials

Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography.

Start date: July 18, 2023
Phase: Phase 2
Study type: Interventional

Does Ketamine-Midazolam have a better efficacy and safety profile compared to Midazolam - Pethidine in Endoscopic Retrograde Cholangiopancreatography (ERCP)?

NCT ID: NCT05770739 Recruiting - Clinical trials for Enhanced Recovery After Surgery

A RCT Study of ERAS in Infants With Choledochal Cyst

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Recently, with reference to the successful experience of accelerated rehabilitation surgery in the field of adult surgery, the investigators have conducted studies on ERAS in pediatric and even infant cholangiectasia surgery to discuss its feasibility and safety. The results showed that some items of ERAS could be safely applied in perioperative management of CBD, and could reduce traumatic stress and promote postoperative recovery. Therefore, the investigators assumed that the ERAS protocols could be safely applied in the treatment of CBD in children and even infants, reducing traumatic stress in children with CBD, promoting postoperative rehabilitation, reducing complications and hospitalization time, reducing hospitalization costs, and saving medical resources.

NCT ID: NCT05620485 Not yet recruiting - Choledochal Cyst Clinical Trials

Timing of Operation in Children With a Prenatal Diagnosis of Choledochal Cyst

CDCPS
Start date: November 15, 2022
Phase: N/A
Study type: Interventional

In this prospective study, we tried to select the operation time according to the cyst size and evaluate the treatment effect.

NCT ID: NCT05404503 Recruiting - Clinical trials for Incidence of Cholangiocarcinoma on Choledochal Cysts

Analysis of the Incidence of Cholangiocarcinoma on Choledochal Cyst in a Western Center

QuiCo
Start date: October 2022
Phase:
Study type: Observational

Choledochal cysts are congenital cystic dilatations of the intra and/or extrahepatic bile duct. They have been considered a rare entity of the child population. Globally, they account for 1% of all biliary pathology benign, with a clearly higher incidence in Asian countries (1/5,000 in China, 1/1,000 in Japan, compared to 1/100,000-150,000 in Western countries). However, the number of adults diagnosed in recent years has increased by up to 70% due to improvements in imaging tests. Currently, the common bile duct malformation is considered a premalignant entity: although the data are not very precise, it is estimated that between 2.6% and 26% of patients diagnosed choledochal cyst, will develop cholangiocarcinoma. In this sense, we must bear in mind that most of the published literature is of Asian origin, where the rate of cholangiocarcinoma is 0.1-71/100,000 compared to 0.1-1.8/100,000 in Europe or 0.6-1/100,000 in the USA. The most used classification to differentiate the types of cysts is that of Todani. Following this classification, we would find a higher rate of malignancy on types I and IV. The recommendations found in the literature refer to the need for surgical intervention for choledochal cysts due to their high rate of malignancy. These recommendations are based on studies conducted in a symptomatic Asian population. We do not usually find in therapeutic algorithms the inclusion of various factors that could be involved in the development of malignancy such as episodes of cholangitis, presence of anomaly in the pancreatobiliary junction, presence of lithiasis in cystic dilatation, etc. Some surveys carried out among the scientific population reflect a lack of consensus on its management: in the same clinical situation, different surgery units specialized in hepatobiliary-pancreatic pathology would act in the opposite way (specifically surgical versus conservative treatment). Bile duct resection is not without complications, both short-term and long-term. Therefore, the patient's symptoms, age or comorbidities can play an important role in decision-making in the treatment of this pathology. This nationwide multicenter retrospective observational study aims to determine the clinical situation of this rare pathology in a Western environment. A retrospective analysis of patients diagnosed with choledochal cyst in the period between 2000 and 2020 is proposed. Demographic variables, risk factors for cholangiocarcinoma, symptoms associated with the cyst and its characteristics, diagnostic method, type of treatment, complications will be analyzed. Malignancy, time, and follow-up method will also be discussed. This study will attempt to answer questions about the incidence of choledochal cysts in our environment, their association with cholangiocarcinoma, the associated morbidity and mortality, as well as the therapeutic and follow-up attitudes adopted in the face of this rare pathology.

NCT ID: NCT05181332 Recruiting - Cirrhosis Clinical Trials

Predictive Models of Hepatic Decompensation and Survival Outcomes in Pediatric Patients With Cirrhosis

Start date: January 1, 2021
Phase:
Study type: Observational

The aim of this study was to developed and validated models to predict hepatic decompensation and survivals in pediatric patients with cirrhosis and compared these models with currently available models.

NCT ID: NCT04319302 Completed - Biliary Obstruction Clinical Trials

Isolated Vascularized Gastric Tube Biliary Enteric Drainage: A Paediatric Case Series Experience.

Start date: January 2005
Phase:
Study type: Observational

This was a retrospective case series experience of paediatric patients who had an Isolated vascularized gastric tube biliary enteric drainage procedure for biliary obstruction over the past five years. We reviewed our experience and outcomes.

NCT ID: NCT03774589 Recruiting - Pancreatic Cancer Clinical Trials

Bilioenteric Anastomosis by Magnetic Compressive Technique

BAMCT
Start date: February 1, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the magnetic compressive anastomosis has a better outcomes than traditional manual anastomosis on bilioenteric anastomosis.

NCT ID: NCT02801500 Recruiting - Clinical trials for Hilar Cholangiocarcinoma

Superior Bilioenteric Anastomosis by Magnetic Compressive Technique

CTREG
Start date: July 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the magnetic compressive anastomosis has a better outcomes than traditional manual anastomosis on superior bilioenteric anastomosis.

NCT ID: NCT02013986 Unknown status - Fracture Clinical Trials

Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children

Start date: September 2013
Phase: Phase 4
Study type: Interventional

Etomidate is an unique drug used for induction of general anesthesia and sedation. Adrenal cortical inhibition by etomidate has received much attention. However wether the circadian rhythm and pulse secretion pattern of cortisol in children are the same as that in adults is not known. Moreover, the effect of etomidate on circadian rhythm changes and clinical outcomes has never been carefully studied in children undergoing surgery. Our hypothesis is that etomidate can relieve the changes of circadian rhythm of salivary cortisol in children for 24-48 hours,and this does not make clinical outcomes worse postoperatively.